Osteoporosis and diabetes

被引：74

作者：

Diane L. Chau

Steven V. Edelman

Manju Chandran

机构：

[1] Department of Geriatric Medicine, VA Sierra Health Care Systems, Univ. of Nevada School of Medicine, Reno, NV 89502

来源：

Current Diabetes Reports | 2003年 / 3卷 / 1期

关键词：

Bone Mineral Density; Osteoporosis; Alendronate; Zoledronic Acid; Raloxifene;

D O I：

10.1007/s11892-003-0051-8

中图分类号：

学科分类号：

摘要：

Osteoporosis is the most prevalent metabolic bone disease in the United States. Although the disease has historically been reported mostly in white women, it can affect individuals of both sexes and all ethnic groups. The presence of osteoporosis related to diabetes is not well acknowledged and the impact of osteoporosis in a diabetic patient is often not considered. Routine screening or initiation of preventive medications for osteoporosis in all patients with type 1 or type 2 diabetes is not recommended at the present time. However, in all patients with diabetes, besides optimal glycemic control, general recommendations regarding adequate dietary calcium intake, regular exercise, and avoidance of other potential risk factors such as smoking should be given. In patients who have positive risk factors for osteoporosis, or in those who present with fractures, evaluation of bone density should be done and respective preventive or therapeutic interventions should be applied. Copyright © 2003 by Current Science Inc.

引用

页码：37 / 42

页数：5

共 49 条

[41] Khan S.A., Kanis J.A., Vasikaran S., Et al., Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis, J. Bone Miner. Res., 12, pp. 1700-1707, (1997)
[42] Reid I.R., Brown J.P., Burckhardt P., Et al., Intravenous zoledronic acid in postmenopausal women with low bone mineral density, N. Engl. J. Med., 346, pp. 653-661, (2002)
[43] Lindsay R., Cosman F., Lobo R.A., Et al., Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial, J. Clin. Endocrinol. Metab., 84, pp. 3076-3081, (1999)
[44] Maugeri D., Panebianco P., Rosso D., Et al., Alendronate reduces the daily consumption of insulin (DCI) in patients with senile type I diabetes and osteoporosis, Arch. Gerontol. Geriatr., 34, pp. 117-122, (2002)
[45] Neer R.M., Arnaud C.D., Zanchetta J.R., Et al., Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N. Engl J. Med., 344, pp. 1434-1441, (2001)
[46] Mundy G., Garrett R., Harris S., Et al., Stimulation of bone formation in vitro and in rodents by statins, Science, 286, pp. 1946-1949, (1999)
[47] Bauer D.C., Black D.M., Van der Klift M., Statin use and fracture: A meta-analysis of 8 observational studies, Bone, 28, SUPPL. 1, (2001)
[48] Okazaki R., Toriumi M., Fukomoto S., Et al., Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro, Endocrinology, 140, pp. 5060-5065, (1999)
[49] Okazaki R., Skeletal effects of thiazolidinediones, Nippon Rinsho, 58, pp. 456-460, (2000)

← 1 2 3 4 5 →